Loading...
Market
Story
Eli Lilly's Mounjaro Approved for Hong Kong Launch by Year-End 2024, Stock at $LLY
Oct 28, 2024, 01:08 AM
Eli Lilly & Co. has received approval to launch its weight-loss drug, Mounjaro, in Hong Kong, with sales expected to begin by the end of 2024. This development marks a significant milestone as it positions Mounjaro to be the first weight-loss drug of its kind available in the China region. The approval comes amid ongoing discussions regarding the broader implications of drug shortages and FDA oversight, as highlighted by recent reports. Eli Lilly's stock, trading under the ticker $LLY, is closely monitored as the company expands its market presence.
View original story
Similar markets
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%
Weight Loss • 25%
Type 2 Diabetes • 25%
Both equally • 25%
Other • 25%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Mounjaro > 50% • 25%
Mounjaro 30-50% • 25%
Mounjaro 10-30% • 25%
Mounjaro < 10% • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
